Cure My Disease

Don't miss your cure!

 Log in / Sign up

Home Eye-Pressure checks could slow glaucoma vision loss

NCT ID NCT05940623

Disease control Sponsor: The University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

This trial tests whether people with newly diagnosed glaucoma can better control their eye pressure by measuring it at home and sharing the readings with their doctor. Participants either use a home device plus a smartphone app to guide treatment, or receive standard care with a smartphone app alone. The goal is to see if the home monitoring approach leads to lower eye pressure and slower damage to the optic nerve over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Home intraocular pressure telemonitoring with a smartphone-based intervention
What this could lead to
If it works, this approach could help people with glaucoma keep their eye pressure lower and slow vision loss, potentially reducing the risk of blindness.
What could go wrong
The trial is relatively small and early, and it is not yet clear if home monitoring will lead to better outcomes than standard care. Some people may find the self-measurement routine difficult to maintain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 142 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Newly diagnosed primary open-angle glaucoma (POAG) * Best corrected visual acuity (VA) ≥20/40 for the included eye(s) Exclusion Criteria: * IOP \>35 millimeters of mercury (mmHg) * Dry eye syndrome * Central corneal thickness \<500μm or \>600μm * Failure to complete the iCare Home certification procedure at the baseline visits * Only one eye with functional vision * Inability to perform reliable visual field (VF) * Pathological myopia (eyes with axial length≥26mm with lacquer cracks and chorioretinal atrophy) * Suboptimal quality of optical coherence tomography (OCT) images (described below in RNFL imaging) * Previous intraocular surgery or corneal refractive surgery other than uncomplicated cataract extraction * Diabetic retinopathy/maculopathy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glaucoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glaucoma open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glaucoma Intraocular pressure Primary open angle glaucoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • HKU Eye Centre

    RECRUITING

    Wong Chuk Hang, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.